皮下免疫治疗变应原：安全性评估。
Subcutaneous immunotherapy with aeroallergens: safety profile assessment.
机构信息
Immunoallergology Service, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Lisbon, Portugal.
Immunoallergology Unit, Hospital Dr. Nélio Mendonça, SESARAM, EPE, Funchal, Portugal.
出版信息
Eur Ann Allergy Clin Immunol. 2022 Mar;54(2):77-83. doi: 10.23822/EurAnnACI.1764-1489.194. Epub 2021 Mar 16.
Severe systemic reactions (SR) to allergen subcutaneous immunotherapy (SCIT) are rare but local reactions (LR) are common. We aimed to characterize the type of reactions and safety profile. Retrospective analysis of medical record from patients under SCIT between 2013-2016. Total of 7372 SCIT injections in 323 patients: 52% female; mean age 30 years (SD 13); mean treatment time 19 months (SD 13). There were 57 patients (17.6% of population, 70% female) with at least one adverse reaction, for 93 reactions described (1.3% injections). There were 79 LR (1.1% injections) in 46(14.2%) patients: 36 in build-up, 43 in maintenance. There were 14 SR (0.19% injections) in 12(3.7%) patients: 12 in build-up, 2 in maintenance. All SR were grade 1. The majority of reactions were caused by mite SCIT (69.9%). SCIT is safe and well tolerated, with no report of SR grade > 1.
严重的全身性过敏反应（SR）对过敏原皮下免疫治疗（SCIT）很少见，但局部反应（LR）很常见。我们旨在描述反应类型和安全性概况。
对 2013-2016 年接受 SCIT 的患者的病历进行回顾性分析。323 例患者共接受了 7372 次 SCIT 注射：52%为女性；平均年龄 30 岁（标准差 13）；平均治疗时间为 19 个月（标准差 13）。有 57 例患者（17.6%的人群，70%为女性）至少有一次不良反应，共描述了 93 次反应（占注射次数的 1.3%）。46 例患者（14.2%）发生 79 次 LR（占注射次数的 1.1%）：36 次在递增期，43 次在维持期。12 例患者（3.7%）发生 14 次 SR（占注射次数的 0.19%）：12 次在递增期，2 次在维持期。所有 SR 均为 1 级。大多数反应是由螨类 SCIT 引起的（69.9%）。
SCIT 是安全且耐受良好的，没有报告 SR 等级>1。
Zotero 插件